The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Integra Lifesciences Holdings Corp’s stock clocked out at $13.14, up 6.22% from its previous closing price of $12.37. In other words, the price has increased by $6.22 from its previous closing price. On the day, 3.09 million shares were traded. IART stock price reached its highest trading level at $14.07 during the session, while it also had its lowest trading level at $12.995.
Ratios:
To gain a deeper understanding of IART’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.72 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 1.77 whereas as Long-Term Debt/Eq ratio is at 1.77.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’24 when Schwartz Eric sold 4,070 shares for $24.59 per share. The transaction valued at 100,102 led to the insider holds 59,511 shares of the business.
Schwartz Eric bought 4,070 shares of IART for $100,102 on Dec 03 ’24. On Dec 02 ’24, another insider, McBreen Michael J., who serves as the EVP & President, CSS of the company, sold 1,700 shares for $24.16 each. As a result, the insider received 41,064 and left with 56,182 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IART now has a Market Capitalization of 1021139712 and an Enterprise Value of 2708827904. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.63 while its Price-to-Book (P/B) ratio in mrq is 0.67. Its current Enterprise Value per Revenue stands at 1.668 whereas that against EBITDA is 8.453.
Stock Price History:
The Beta on a monthly basis for IART is 1.16, which has changed by -0.45341098 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, IART has reached a high of $27.13, while it has fallen to a 52-week low of $11.06. The 50-Day Moving Average of the stock is 4.18%, while the 200-Day Moving Average is calculated to be -31.64%.
Shares Statistics:
It appears that IART traded 1.34M shares on average per day over the past three months and 1246280 shares per day over the past ten days. A total of 77.71M shares are outstanding, with a floating share count of 65.72M. Insiders hold about 15.44% of the company’s shares, while institutions hold 97.81% stake in the company. Shares short for IART as of 1752537600 were 6465434 with a Short Ratio of 4.82, compared to 1749772800 on 6122978. Therefore, it implies a Short% of Shares Outstanding of 6465434 and a Short% of Float of 13.55.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.91, with high estimates of $0.95 and low estimates of $0.89.
Analysts are recommending an EPS of between $2.25 and $2.19 for the fiscal current year, implying an average EPS of $2.22. EPS for the following year is $2.43, with 12.0 analysts recommending between $2.63 and $2.33.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $415.33M. It ranges from a high estimate of $419.28M to a low estimate of $410.3M. As of the current estimate, Integra Lifesciences Holdings Corp’s year-ago sales were $380.83MFor the next quarter, 9 analysts are estimating revenue of $461.18M. There is a high estimate of $470.69M for the next quarter, whereas the lowest estimate is $449.54M.
A total of 11 analysts have provided revenue estimates for IART’s current fiscal year. The highest revenue estimate was $1.68B, while the lowest revenue estimate was $1.66B, resulting in an average revenue estimate of $1.67B. In the same quarter a year ago, actual revenue was $1.61BBased on 10 analysts’ estimates, the company’s revenue will be $1.74B in the next fiscal year. The high estimate is $1.75B and the low estimate is $1.73B.
